CVS HEALTH Corp (CVS) stock
CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 19/3031% below fair value
$89.79+0.27 (+0.30%)
Close on Nov 12, 2026Market cap $114.84BP/E 10.5Yield 2.96%
Cvs Health ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cvs Health's ebitda for the twelve months ending Sep 30, 2026 was $19.58B, up 105.6% year over year. For fiscal 2025 it was $9.27B, down 29.3% from the year before. Over ten years it grew -2.2% a year on average. The highest annual figure on record is $18.35B in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.27B | -29.3% |
| FY2024 | Dec 31, 2024 | $13.11B | -27.6% |
| FY2023 | Dec 31, 2023 | $18.11B | +48.7% |
| FY2022 | Dec 31, 2022 | $12.18B | -31.6% |
| FY2021 | Dec 31, 2021 | $17.80B | -3.0% |
| FY2020 | Dec 31, 2020 | $18.35B | +12.2% |
| FY2019 | Dec 31, 2019 | $16.36B | +142.7% |
| FY2018 | Dec 31, 2018 | $6.74B | -43.9% |
| FY2017 | Dec 31, 2017 | $12.02B | -6.6% |
| FY2016 | Dec 31, 2016 | $12.86B | +11.2% |
| FY2015 | Dec 31, 2015 | $11.57B | +7.8% |
| FY2014 | Dec 31, 2014 | $10.73B | +8.3% |
| FY2013 | Dec 31, 2013 | $9.91B | +10.5% |
| FY2012 | Dec 31, 2012 | $8.96B | +13.5% |
| FY2011 | Dec 31, 2011 | $7.90B | +3.9% |
| FY2010 | Dec 31, 2010 | $7.61B | -2.7% |
| FY2009 | Dec 31, 2009 | $7.81B | +6.7% |
| FY2008 | Dec 31, 2008 | $7.32B | +24.3% |
| FY2007 | Dec 29, 2007 | $5.89B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.70B | – |
| Q2 FY2026 | Jun 30, 2026 | $5.83B | +64.1% |
| Q1 FY2026 | Mar 31, 2026 | $5.80B | +28.0% |
| Q4 FY2025 | Dec 31, 2025 | $3.26B | -7.3% |
| Q3 FY2025 | Sep 30, 2025 | -$2.07B | -204.0% |
| Q2 FY2025 | Jun 30, 2025 | $3.55B | -15.3% |
| Q1 FY2025 | Mar 31, 2025 | $4.53B | +32.8% |
| Q4 FY2024 | Dec 31, 2024 | $3.52B | -22.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.99B | -58.6% |
| Q2 FY2024 | Jun 30, 2024 | $4.20B | -3.3% |
| Q1 FY2024 | Mar 31, 2024 | $3.41B | -23.3% |
| Q4 FY2023 | Dec 31, 2023 | $4.51B | -4.1% |
| Q3 FY2023 | Sep 30, 2023 | $4.82B | – |
| Q2 FY2023 | Jun 30, 2023 | $4.34B | -24.6% |
| Q1 FY2023 | Mar 31, 2023 | $4.45B | -3.2% |
| Q4 FY2022 | Dec 31, 2022 | $4.70B | +36.9% |
| Q3 FY2022 | Sep 30, 2022 | -$2.87B | -168.4% |
| Q2 FY2022 | Jun 30, 2022 | $5.75B | +5.3% |
| Q1 FY2022 | Mar 31, 2022 | $4.59B | -2.3% |
| Q4 FY2021 | Dec 31, 2021 | $3.44B | -6.2% |
| Q3 FY2021 | Sep 30, 2021 | $4.20B | -3.9% |
| Q2 FY2021 | Jun 30, 2021 | $5.46B | -5.5% |
| Q1 FY2021 | Mar 31, 2021 | $4.70B | +3.5% |
| Q4 FY2020 | Dec 31, 2020 | $3.66B | -11.4% |
| Q3 FY2020 | Sep 30, 2020 | $4.36B | +8.5% |
| Q2 FY2020 | Jun 30, 2020 | $5.78B | +31.3% |
| Q1 FY2020 | Mar 31, 2020 | $4.54B | +19.5% |
| Q4 FY2019 | Dec 31, 2019 | $4.13B | +153.4% |
| Q3 FY2019 | Sep 30, 2019 | $4.02B | +25.9% |
| Q2 FY2019 | Jun 30, 2019 | $4.40B | – |
| Q1 FY2019 | Mar 31, 2019 | $3.80B | +44.0% |
| Q4 FY2018 | Dec 31, 2018 | $1.63B | -56.3% |
| Q3 FY2018 | Sep 30, 2018 | $3.19B | +2.4% |
| Q2 FY2018 | Jun 30, 2018 | -$726.00M | -126.5% |
| Q1 FY2018 | Mar 31, 2018 | $2.64B | +9.2% |
| Q4 FY2017 | Dec 31, 2017 | $3.74B | +3.0% |
| Q3 FY2017 | Sep 30, 2017 | $3.12B | – |
| Q2 FY2017 | Jun 30, 2017 | $2.74B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.42B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.63B | – |
See a number that looks wrong?